首页> European journal of pharmacology> Fruquintinib/HMPL-013 ameliorates cognitive impairments and pathology in a mouse model of cerebral amyloid angiopathy (CAA).

Fruquintinib/HMPL-013 ameliorates cognitive impairments and pathology in a mouse model of cerebral amyloid angiopathy (CAA).

导出 LinkOut

翻译打印收藏纠错

第一作者： Guijuan,Zhou

第一单位： Department of Neurology, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang 421099, Hunan Province, China; Department of Rehabilitation Medicine, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang 421099, Hunan Province, China.

作者： Guijuan,Zhou ^[1] ; Tao,Xiang ^[2] ; Yan,Xu ^[2] ; Bing,He ^[2] ; Lin,Wu ^[2] ; Guanghua,Zhu ^[2] ; Juan,Xie ^[2] ; Lan,Yao ^[2] ; Zijian,Xiao ^[3]

作者单位： Department of Neurology, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang 421099, Hunan Province, China; Department of Rehabilitation Medicine, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang 421099, Hunan Province, China. ^[1] Department of Neurology, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang 421099, Hunan Province, China. ^[2] Department of Neurology, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang 421099, Hunan Province, China. Electronic address: xiaozijian_edu@yeah.net. ^[3]

关键词 Aβ metabolism Cerebral amyloid angiopathy (CAA)HMPL-013 Inflammation and neuron death VEGF/VEGFR-1,-2